New Scaffold Technology Shows Promise for Improving Islet Transplant Survival

For people with Type 1 diabetes, pancreatic islet transplantation—which transfers insulin-producing cells from a donor pancreas—can reduce or eliminate the need for insulin injections. However, current transplant methods face a significant challenge: keeping the transplanted cells alive and functional.

The most common transplant location today is the liver, but researchers have long explored whether placing islets under the skin might work better. The subcutaneous space is easier to access and less invasive, but it has a critical drawback: poor blood supply. Without adequate blood vessels to deliver oxygen and nutrients, transplanted islet cells die quickly, meaning doctors must transplant more cells to achieve the same result.

A team of researchers tested whether a specially designed material could solve this blood supply problem. They created a combination scaffold using two components: fibrin hydrogel (a natural substance that forms a supportive framework) and microvascular fragments (tiny pieces of blood vessels).

In their rat study, they tested several strategies: preparing the transplant site in advance with the scaffold, transplanting islets together with the scaffold, or using traditional transplantation without pre-treatment. The goal was to see whether the scaffold could help new blood vessels form and improve islet survival.

The research team monitored the transplanted islets over 28 days using blood sugar tests, glucose tolerance tests, and tissue analysis. Rats that received the fibrin hydrogel and microvascular fragment combination—either as pre-treatment or together with the islet transplant—showed the strongest results.

These rats achieved normal blood sugar levels using 1,500 islet equivalents (a unit of measurement for islet cell quantity). In comparison, rats receiving standard transplants without the scaffold needed 3,000 islet equivalents to reach the same outcome. The scaffold group also showed better glucose tolerance, higher insulin levels, and increased markers of blood vessel growth in the transplant tissue.

If this approach translates to human testing, it could make islet transplantation more practical in several ways: using fewer donor cells per transplant (important because donor pancreases are scarce), reducing the invasiveness of the procedure by using subcutaneous rather than liver transplants, and improving transplant success rates.

This research represents an early step in developing better transplant methods. Researchers are still in the animal testing phase, and many more studies will be needed before this technology could be tested in people with Type 1 diabetes. The work does highlight how engineering new materials to support transplanted cells is becoming an important part of diabetes research.

Source: Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.